{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:06:35Z","timestamp":1791331595042,"version":"4.3.1"},"reference-count":295,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":721,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1310"],"award-info":[{"award-number":["CRC 1310"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","award":["01KX2021"],"award-info":[{"award-number":["01KX2021"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.immuni.2022.05.005","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T05:08:23Z","timestamp":1652418503000},"page":"925-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"title":["Antibody-mediated neutralization of SARS-CoV-2"],"prefix":"10.1016","volume":"55","author":[{"given":"Henning","family":"Gruell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Vanshylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher O.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kreer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-1792","authenticated-orcid":false,"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2022.05.005_bib1","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc2119432","article-title":"Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib3","first-page":"622","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.immuni.2022.05.005_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/M21-3507","article-title":"Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial","volume":"175","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with covid-19","volume":"384","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib7","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","volume":"184","author":"Amanat","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.cell.2021.02.010","article-title":"Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection","volume":"184","author":"Anderson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","article-title":"Extremely potent human monoclonal antibodies from COVID-19 convalescent patients","volume":"184","author":"Andreano","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103154118","article-title":"SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma","volume":"118","author":"Andreano","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.immuni.2022.05.005_bib12","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib14","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib16","doi-asserted-by":"crossref","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.immuni.2022.05.005_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2021.22898","article-title":"Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection","volume":"327","author":"Bates","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2022.05.005_bib21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib23","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"Begin","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","article-title":"Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion","volume":"588","author":"Benton","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib25","doi-asserted-by":"crossref","first-page":"109433","DOI":"10.1016\/j.celrep.2021.109433","article-title":"A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations","volume":"36","author":"Bertoglio","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","article-title":"Fc\u03b3 receptor function and the design of vaccination strategies","volume":"47","author":"Bournazos","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib31","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent Neutralizing Antibodies against SARS-CoV-2 Identified by high-throughput single-cell sequencing of convalescent patients' B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Carreno","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib35","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in\u00a0vitro and in\u00a0vivo activity against SARS-CoV-2","author":"Cathcart","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.immuni.2022.05.005_bib36","doi-asserted-by":"crossref","first-page":"109928","DOI":"10.1016\/j.celrep.2021.109928","article-title":"Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain","volume":"37","author":"Cerutti","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib38","doi-asserted-by":"crossref","first-page":"e0253487","DOI":"10.1371\/journal.pone.0253487","article-title":"The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody","volume":"16","author":"Chan","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.immuni.2022.05.005_bib44","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.cell.2020.10.051","article-title":"Quick COVID-19 Healers sustain anti-SARS-CoV-2 antibody production","volume":"183","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib39","doi-asserted-by":"crossref","first-page":"109604","DOI":"10.1016\/j.celrep.2021.109604","article-title":"Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals","volume":"36","author":"Chen","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib40","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cpt.2405","article-title":"First-in-human study of bamlanivimab in a randomized trial of hospitalized patients with COVID-19","volume":"110","author":"Chen","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.immuni.2022.05.005_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03720-y","article-title":"In\u00a0vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib46","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-021-04060-7","article-title":"Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination","volume":"600","author":"Cho","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib48","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib49","article-title":"Emergence of SARS-CoV-2 resistance with monoclonal antibody therapy","author":"Choudhary","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.immuni.2022.05.005_bib50","first-page":"188","article-title":"A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques","volume":"3","author":"Cobb","year":"2022","journal-title":"Med (N Y)"},{"key":"10.1016\/j.immuni.2022.05.005_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2022.05.005_bib52","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"Copin","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib53","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.abl8912","article-title":"Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates","volume":"374","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib54","doi-asserted-by":"crossref","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib55","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib56","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2022.05.005_bib57","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8\u00a0months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib58","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib59","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib60","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib61","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","article-title":"Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail","volume":"6","author":"Dong","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib62","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 Months after the second dose of mRNA-1273 vaccine for covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","article-title":"Antibodies and B cell memory in viral immunity","volume":"27","author":"Dorner","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib65","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","article-title":"Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy","volume":"183","author":"Du","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib66","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.immuni.2022.05.005_bib294","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting","volume":"26","author":"Edridge","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/gch2.1018","article-title":"Data, disease and diplomacy: GISAID's innovative contribution to global health","volume":"1","author":"Elbe","year":"2017","journal-title":"Glob. Chall."},{"key":"10.1016\/j.immuni.2022.05.005_bib68","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Elsner","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib69","doi-asserted-by":"crossref","first-page":"103951","DOI":"10.1016\/j.isci.2022.103951","article-title":"No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults","volume":"25","author":"Ercanoglu","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.immuni.2022.05.005_bib70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.chom.2022.01.006","article-title":"Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission","volume":"30","author":"Escalera","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib71","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1038\/s41467-020-17371-6","article-title":"Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein","volume":"11","author":"Fan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib72","doi-asserted-by":"crossref","first-page":"eabl5842","DOI":"10.1126\/sciimmunol.abl5842","article-title":"Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses","volume":"6","author":"Feldman","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib73","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib75","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/s41467-021-25949-x","article-title":"SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms","volume":"12","author":"Froberg","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib77","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing antibodies and protection against Omicron","volume":"185","author":"Gagne","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib78","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib79","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib80","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1038\/s41596-021-00554-w","article-title":"Effective high-throughput isolation of fully human antibodies targeting infectious pathogens","volume":"16","author":"Gieselmann","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.immuni.2022.05.005_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib82","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib83","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib84","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2022.05.005_bib85","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib86","doi-asserted-by":"crossref","first-page":"eabi9915","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib87","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib89","doi-asserted-by":"crossref","first-page":"1930636","DOI":"10.1080\/19420862.2021.1930636","article-title":"A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351","volume":"13","author":"Gu","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.immuni.2022.05.005_bib90","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib91","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/s41467-021-22926-2","article-title":"A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes","volume":"12","author":"Guo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib92","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib93","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2022.05.005_bib94","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/infdis\/jiab289","article-title":"SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model","volume":"223","author":"Haagmans","year":"2021","journal-title":"J.\u00a0Infect Dis."},{"key":"10.1016\/j.immuni.2022.05.005_bib95","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib96","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","article-title":"Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T\u00a0cell responses","volume":"23","author":"Hall","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib97","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/v13081498","article-title":"Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection","volume":"13","author":"Halwe","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.immuni.2022.05.005_bib98","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib99","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib101","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.abh2315","article-title":"Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study","volume":"374","author":"Hastie","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib102","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nri3689","article-title":"Follicular dendritic cells: dynamic antigen libraries","volume":"14","author":"Heesters","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib103","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib104","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib106","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex\u00a0vivo and transmission in\u00a0vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.07.002","article-title":"Neutralization of SARS-CoV-2 by destruction of the prefusion spike","volume":"28","author":"Huo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib108","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/imr.12670","article-title":"Assessing human B cell repertoire diversity and convergence","volume":"284","author":"Imkeller","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2022.05.005_bib110","doi-asserted-by":"crossref","first-page":"eabe0367","DOI":"10.1126\/sciimmunol.abe0367","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"Iyer","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib111","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib112","doi-asserted-by":"crossref","first-page":"109353","DOI":"10.1016\/j.celrep.2021.109353","article-title":"Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects","volume":"36","author":"Jennewein","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib113","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.lanepe.2021.100164","article-title":"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany","volume":"8","author":"Jensen","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.immuni.2022.05.005_bib114","doi-asserted-by":"crossref","first-page":"110188","DOI":"10.1016\/j.celrep.2021.110188","article-title":"Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies","volume":"37","author":"Jette","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib115","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-immunol-032712-100001","article-title":"Control of human viral infections by natural killer cells","volume":"31","author":"Jost","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib117","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib118","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1172\/JCI140200","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients","volume":"130","author":"Joyner","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2022.05.005_bib119","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04702-4","article-title":"FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation","author":"Junqueira","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cell.2020.08.025","article-title":"Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19","volume":"183","author":"Kaneko","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib122","doi-asserted-by":"crossref","first-page":"eabj2901","DOI":"10.1126\/sciimmunol.abj2901","article-title":"Early cross-coronavirus reactive signatures of humoral immunity against COVID-19","volume":"6","author":"Kaplonek","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib123","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib124","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.chom.2021.10.003","article-title":"Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner","volume":"29","author":"Keeton","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20411\/pai.v6i1.441","article-title":"Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva","volume":"6","author":"Ketas","year":"2021","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.immuni.2022.05.005_bib126","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.immuni.2022.05.005_bib127","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41577-020-00471-1","article-title":"Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models","volume":"20","author":"Khoury","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib130","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clinthera.2021.08.009","volume":"43","author":"Kim","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.immuni.2022.05.005_bib131","doi-asserted-by":"crossref","first-page":"eabd6990","DOI":"10.1126\/scitranslmed.abd6990","article-title":"Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals","volume":"13","author":"Kim","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib133","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib134","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib136","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with covid-19","volume":"385","author":"Korley","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib137","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib138","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib139","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO international standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib140","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib141","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib142","article-title":"A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccination","author":"Lanini","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.immuni.2022.05.005_bib143","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib144","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41586-021-03925-1","article-title":"Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies","volume":"598","author":"Lempp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib146","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6\u00a0months","volume":"385","author":"Levin","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib147","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19","author":"Levin","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib148","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.cell.2021.06.021","article-title":"In\u00a0vitro and in\u00a0vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib149","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib150","doi-asserted-by":"crossref","first-page":"e0106321","DOI":"10.1128\/AAC.01063-21","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: a randomized, double-blind, placebo-controlled, phase I study","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.immuni.2022.05.005_bib151","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib152","author":"Lilly"},{"key":"10.1016\/j.immuni.2022.05.005_bib153","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib154","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib155","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib156","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib157","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib158","doi-asserted-by":"crossref","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.immuni.2022.05.005_bib159","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib160","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib161","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02005-20","article-title":"Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients","volume":"58","author":"Luchsinger","year":"2020","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib162","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib163","doi-asserted-by":"crossref","first-page":"eabj7125","DOI":"10.1126\/scitranslmed.abj7125","article-title":"A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice","volume":"14","author":"Martinez","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib164","doi-asserted-by":"crossref","first-page":"109450","DOI":"10.1016\/j.celrep.2021.109450","article-title":"Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice","volume":"36","author":"Martinez","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.immuni.2022.05.005_bib165","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib166","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.abf6950","article-title":"Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape","volume":"371","author":"McCarthy","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib167","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib168","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/22221751.2021.1960900","article-title":"Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody","volume":"10","author":"Meng","year":"2021","journal-title":"Emerg. Microbes Infect"},{"key":"10.1016\/j.immuni.2022.05.005_bib169","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib170","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib171","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.immuni.2021.06.015","article-title":"Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants","volume":"54","author":"Moriyama","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib172","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","article-title":"SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans","volume":"185","author":"Mudd","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04778-y","article-title":"Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost","author":"Muecksch","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib174","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"Muecksch","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib175","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib176","author":"Mullen"},{"key":"10.1016\/j.immuni.2022.05.005_bib177","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib178","doi-asserted-by":"crossref","first-page":"eabl6251","DOI":"10.1126\/science.abl6251","article-title":"Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain","volume":"375","author":"Nabel","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib179","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de novo humoral immunity to SARS-CoV-2 in humans","volume":"370","author":"Ng","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib180","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib181","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic coVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial","volume":"327","author":"O'Brien","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2022.05.005_bib182","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib183","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"Perez-Then","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib184","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib185","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib186","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib187","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib188","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib189","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccin. Immunol"},{"key":"10.1016\/j.immuni.2022.05.005_bib190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(22)00101-5","article-title":"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial","volume":"399","author":"Polizzotto","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib191","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1093\/cid\/ciaa1803","article-title":"Absence of severe acute respiratory syndrome coronavirus 2 neutralizing activity in prepandemic sera from individuals with recent seasonal coronavirus infection","volume":"73","author":"Poston","year":"2021","journal-title":"Clin. Infect Dis."},{"key":"10.1016\/j.immuni.2022.05.005_bib192","doi-asserted-by":"crossref","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib193","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.abf4830","article-title":"Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody","volume":"371","author":"Rappazzo","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib194","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.immuni.2022.05.005_bib195","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib196","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib197","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T\u00a0cell responses to variants after first vaccine dose","volume":"372","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib198","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","article-title":"Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity","volume":"53","author":"Ripperger","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib199","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib200","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib201","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib202","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"R\u00f6ltgen","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib203","doi-asserted-by":"crossref","first-page":"eabe0240","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"R\u00f6ltgen","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib204","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib205","doi-asserted-by":"crossref","first-page":"e20201993","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in\u00a0vivo","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib206","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.cell.2021.04.032","article-title":"B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV","volume":"184","author":"Scheid","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib207","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma neutralization of the SARS-CoV-2 Omicron variant","volume":"386","author":"Schmidt","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib208","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","article-title":"High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape","volume":"600","author":"Schmidt","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib209","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.immuni.2021.08.013","article-title":"A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants","volume":"54","author":"Schmitz","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib210","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib211","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib212","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib213","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib214","doi-asserted-by":"crossref","first-page":"e0052721","DOI":"10.1128\/JCM.00527-21","article-title":"Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays","volume":"59","author":"Sholukh","year":"2021","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib215","doi-asserted-by":"crossref","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"GISAID: global initiative on sharing all influenza data - from vision to reality","volume":"22","author":"Shu","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.immuni.2022.05.005_bib216","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib217","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/S0140-6736(21)01897-3","article-title":"How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic","volume":"398","author":"Singh","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib218","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41590-021-01028-7","article-title":"Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection","volume":"22","author":"Smith","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib219","article-title":"The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN","author":"Soh","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.immuni.2022.05.005_bib220","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","article-title":"Maturation and persistence of the anti-SARS-CoV-2 memory B cell response","volume":"184","author":"Sokal","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib221","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/s41467-021-23074-3","article-title":"Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection","volume":"12","author":"Song","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib222","first-page":"eabg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib223","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","article-title":"SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape","volume":"597","author":"Starr","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib224","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib225","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.immuni.2022.05.005_bib226","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.immuni.2022.05.005_bib227","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib228","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.immuni.2022.05.005_bib229","doi-asserted-by":"crossref","first-page":"e0239521","DOI":"10.1128\/mBio.02395-21","article-title":"Neutralizing monoclonal antibodies that target the spike receptor binding domain confer Fc receptor-independent protection against SARS-CoV-2 infection in syrian hamsters","volume":"12","author":"Su","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.immuni.2022.05.005_bib230","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib231","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib232","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112703118","article-title":"Nanometer-resolution in\u00a0situ structure of the SARS-CoV-2 postfusion spike protein","volume":"118","author":"Tai","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.immuni.2022.05.005_bib233","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib234","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1038\/s41467-021-24123-7","article-title":"Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain","volume":"12","author":"Tan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib236","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib237","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3201\/eid2805.220271","article-title":"Cross-variant neutralizing serum activity after SARS-CoV-2 breakthrough infections","volume":"28","author":"Tober-Lau","year":"2022","journal-title":"Emerg. Infect Dis."},{"key":"10.1016\/j.immuni.2022.05.005_bib238","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2213-2600(21)00456-2","article-title":"Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers","volume":"9","author":"Tober-Lau","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib239","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1016\/j.cell.2021.07.025","article-title":"Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike","volume":"184","author":"Tong","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib240","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib241","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib242","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib243","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib244","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","article-title":"Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy","volume":"54","author":"Ullah","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib245","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib246","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib247","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2021.04.015","article-title":"Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans","volume":"29","author":"Vanshylla","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib248","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chom.2021.12.010","article-title":"Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers","volume":"30","author":"Vanshylla","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2022.05.005_bib249","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(22)00135-9","article-title":"Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults","volume":"22","author":"Vanshylla","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.immuni.2022.05.005_bib250","doi-asserted-by":"crossref","first-page":"109942","DOI":"10.1016\/j.celrep.2021.109942","article-title":"Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation","volume":"37","author":"Verma","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib251","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib252","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib253","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.abg5268","article-title":"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes","volume":"372","author":"Voss","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib254","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib255","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2022.01.011","article-title":"SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses","volume":"185","author":"Walls","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib256","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib257","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib259","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1038\/s41467-020-19568-1","article-title":"Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib258","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib261","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib262","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.04.003","article-title":"Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins","author":"Wang","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2022.05.005_bib295","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib263","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib264","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib265","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib266","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.immuni.2022.05.005_bib267","doi-asserted-by":"crossref","first-page":"109433","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib268","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib269","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2022.05.005_bib270","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib271","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2022.05.005_bib272","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1038\/s41467-020-19146-5","article-title":"Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein","volume":"11","author":"Wrobel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib273","doi-asserted-by":"crossref","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","article-title":"An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain","volume":"33","author":"Wu","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib274","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib275","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","article-title":"Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy","volume":"599","author":"Yamin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib276","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib277","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16\u00a0months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.immuni.2022.05.005_bib278","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular Architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib279","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","article-title":"Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies","volume":"538","author":"Yuan","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.immuni.2022.05.005_bib281","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib282","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.immuni.2022.05.005_bib283","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib284","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in\u00a0vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2022.05.005_bib285","article-title":"Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies","author":"Zhang","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.immuni.2022.05.005_bib286","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.immuni.2022.05.005_bib287","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib288","doi-asserted-by":"crossref","first-page":"eabi9215","DOI":"10.1126\/scitranslmed.abi9215","article-title":"A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection","volume":"14","author":"Zhou","year":"2022","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.immuni.2022.05.005_bib289","doi-asserted-by":"crossref","first-page":"108699","DOI":"10.1016\/j.celrep.2021.108699","article-title":"Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD","volume":"34","author":"Zhou","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2022.05.005_bib290","doi-asserted-by":"crossref","first-page":"nwaa297","DOI":"10.1093\/nsr\/nwaa297","article-title":"Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2","volume":"8","author":"Zhu","year":"2021","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.immuni.2022.05.005_bib291","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised humoral functional evolution Tracks with SARS-CoV-2 mortality","volume":"183","author":"Zohar","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2022.05.005_bib292","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2022.05.005_bib293","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat. Med."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761322002254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761322002254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:16:43Z","timestamp":1761034603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761322002254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":295,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1074761322002254"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2022.05.005","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-mediated neutralization of SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2022.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}